Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy

Autor:	Kiyotaka Ishijima, Tatsuya Chiba, Shigeo Tsukahara, Jhoji Tanabe, Osamu Hosaka, Toyoaki Tsumura, Satoshi Kogure, Shu Omoto, Takashi Godo, Tadaharu Tsuchiya, Takaharu Tokunaga, Tetsunori Saito, Takashi Shibuya, Kenji Kashiwagi, Kazuyoshi Kitamura, Teruhiko Goto, Fumiko Kashiwagi, Fumihiko Mabuchi
Rok vydání:	2018
Předmět:	Intraocular pressure Article Subject genetic structures Combination therapy Timolol Ocular hypertension 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology medicine Adverse effect business.industry Tafluprost medicine.disease eye diseases Ophthalmology Blood pressure Prostaglandin analog lcsh:RE1-994 Anesthesia Clinical Study 030221 ophthalmology & optometry sense organs business 030217 neurology & neurosurgery medicine.drug
Zdroj:	Journal of Ophthalmology Journal of Ophthalmology, Vol 2018 (2018)
ISSN:	2090-0058 2090-004X
Popis:	Purpose. To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods. Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results. Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P<0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. Conclusions. Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116684c0d1c5bdf728a5d31882632992 https://doi.org/10.1155/2018/8456764 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.